Safety and clinical activity of atezolizumab (atezo) + radium-223 dichloride (r-223) in 2L metastatic castration-resistant prostate cancer (mCRPC): Results from a phase Ib clinical trial.
Publication
, Conference
Morris, MJ; Fong, L; Petrylak, DP; Sartor, AO; Higano, CS; Pagliaro, LC; Alva, AS; Appleman, LJ; Tan, W; Vaishampayan, UN; Porcu, R; Tayama, D ...
Published in: JOURNAL OF CLINICAL ONCOLOGY
2020
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2020
Volume
38
Issue
15
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Morris, M. J., Fong, L., Petrylak, D. P., Sartor, A. O., Higano, C. S., Pagliaro, L. C., … Armstrong, A. J. (2020). Safety and clinical activity of atezolizumab (atezo) + radium-223 dichloride (r-223) in 2L metastatic castration-resistant prostate cancer (mCRPC): Results from a phase Ib clinical trial. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 38).
Morris, Michael J., Lawrence Fong, Daniel Peter Petrylak, A Oliver Sartor, Celestia S. Higano, Lance C. Pagliaro, Ajjai Shivaram Alva, et al. “Safety and clinical activity of atezolizumab (atezo) + radium-223 dichloride (r-223) in 2L metastatic castration-resistant prostate cancer (mCRPC): Results from a phase Ib clinical trial.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 38, 2020.
Morris MJ, Fong L, Petrylak DP, Sartor AO, Higano CS, Pagliaro LC, et al. Safety and clinical activity of atezolizumab (atezo) + radium-223 dichloride (r-223) in 2L metastatic castration-resistant prostate cancer (mCRPC): Results from a phase Ib clinical trial. In: JOURNAL OF CLINICAL ONCOLOGY. 2020.
Morris, Michael J., et al. “Safety and clinical activity of atezolizumab (atezo) + radium-223 dichloride (r-223) in 2L metastatic castration-resistant prostate cancer (mCRPC): Results from a phase Ib clinical trial.” JOURNAL OF CLINICAL ONCOLOGY, vol. 38, no. 15, 2020.
Morris MJ, Fong L, Petrylak DP, Sartor AO, Higano CS, Pagliaro LC, Alva AS, Appleman LJ, Tan W, Vaishampayan UN, Porcu R, Tayama D, Kadel EE, Yuen KCY, Datye A, Armstrong AJ. Safety and clinical activity of atezolizumab (atezo) + radium-223 dichloride (r-223) in 2L metastatic castration-resistant prostate cancer (mCRPC): Results from a phase Ib clinical trial. JOURNAL OF CLINICAL ONCOLOGY. 2020.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2020
Volume
38
Issue
15
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences